Treatment of Klebsiella Infections

Carbapenem-Susceptible Klebsiella

• The American College of Physicians recommends carbapenems (meropenem, imipenem, or ertapenem) as first-line therapy for carbapenem-susceptible Klebsiella infections, with ertapenem showing similar or better outcomes compared to imipenem/meropenem for bloodstream infections, with moderate certainty of evidence 1, 2
• Piperacillin-tazobactam is an option for severe infections with anti-Pseudomonas coverage needed, according to the World Journal of Emergency Surgery 3

Carbapenem-Resistant Klebsiella (CRKP)

• The Infectious Diseases Society of America recommends ceftazidime-avibactam 2.5g IV q8h as first-line therapy for CRKP infections, with a strong recommendation and moderate certainty, and a clinical success rate of 81.6% in complicated intra-abdominal infections 1, 4
• Meropenem-vaborbactam 4g IV q8h is equally effective as first-line therapy for CRKP infections, with a strong recommendation and moderate certainty, and is preferred for pneumonia due to superior epithelial lining fluid penetration 1, 5
• Imipenem-cilastatin-relebactam 1.25g IV q6h is an alternative therapy for CRKP infections, with a conditional recommendation and low certainty 4, 5

Dosing Regimens for CRKP

• The duration of therapy for bloodstream infections is 7-14 days, according to the Journal of Microbiology, Immunology and Infection 5
• The duration of therapy for complicated urinary tract infections is 5-7 days, according to the Journal of Microbiology, Immunology and Infection 5
• The duration of therapy for complicated intra-abdominal infections is 5-7 days, according to the Journal of Microbiology, Immunology and Infection 5
• The duration of therapy for hospital-acquired/ventilator-associated pneumonia is 10-14 days, according to the Journal of Microbiology, Immunology and Infection 5

Combination Therapy Considerations

• Combination therapy with two or more in vitro active antibiotics is recommended for severe CRKP infections with high mortality risk, according to Clinical Microbiology and Infection, with an adjusted HR of 0.56 and 95% CI 0.34-0.91 6
• Monotherapy with newer agents (ceftazidime-avibactam, meropenem-vaborbactam) is sufficient for non-severe infections, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4

Critical Pitfalls and Caveats

• Cefepime should be avoided for ESBL-producing Klebsiella when MIC is in the susceptible dose-dependent category, according to Clinical Microbiology and Infection, due to higher mortality (p=0.045) 2
• Cephamycins (flomoxef, cefmetazole) show increased mortality when MIC is 2-8 mg/L despite susceptibility, according to Clinical Microbiology and Infection, with an adjusted OR of 5.7 and 95% CI 1.9-16.8 2
• Fluoroquinolones are no longer appropriate first-line due to widespread resistance, according to the World Journal of Emergency Surgery 3
• Piperacillin-tazobactam use is controversial for ESBL infections despite in vitro susceptibility, according to the World Journal of Emergency Surgery 3
• Ceftazidime-avibactam resistance emergence occurs in 0-12.8% of KPC-producing isolates during treatment, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4
• Rapid molecular testing should be obtained to identify specific carbapenemase types (KPC vs OXA-48 vs MBL) to guide appropriate therapy, according to Praxis Medical Insights: Practical Summaries of Clinical Guidelines 4

Antibiotic Selection for Klebsiella pneumoniae Wound Infections

Treatment for MBL-Producing Strains

• For metallo-β-lactamase (MBL)-producing strains, the combination of ceftazidime-avibactam plus aztreonam is recommended with 70-90% efficacy, as stated by the Clinical Microbiology and Infection guideline society 7
• This combination is active against MBL producers where other options fail, according to the Clinical Microbiology and Infection guideline society 7

Combination Therapy for Severe CRKP Infections

• Combination therapy with two or more in vitro active antibiotics is recommended for severe CRKP infections, particularly in critically ill patients, with lower 14-day mortality compared to monotherapy (adjusted HR 0.56, 95% CI 0.34-0.91), as stated by the Clinical Microbiology and Infection guideline society 7
• The Clinical Microbiology and Infection guideline society recommends combination therapy, particularly when using polymyxin or tigecycline-based regimens 7

High-Dose Carbapenem Combinations

• For KPC-producing K. pneumoniae with elevated MICs, high-dose extended-infusion meropenem (6g/day, 3-hour infusion) combined with polymyxin may be effective even when MICs are ≤16 mg/L, with low-certainty evidence supporting this approach over polymyxin monotherapy, as stated by the Clinical Microbiology and Infection guideline society 7

Double-Carbapenem Therapy

• Double-carbapenem therapy (ertapenem plus another carbapenem) may be considered when options are limited, though evidence remains insufficient, according to the Clinical Microbiology and Infection guideline society 7
• The Clinical Microbiology and Infection guideline society suggests that observational studies indicate a potential benefit of double-carbapenem therapy, but lack of adjustment for confounders limits conclusions 7

Treatment of Carbapenem-Resistant Klebsiella pneumoniae

First-Line Treatment Options

• The International Society for Antimicrobial Chemotherapy recommends ceftazidime-avibactam 2.5g IV q8h or meropenem-vaborbactam 4g IV q8h as first-line therapy for carbapenem-resistant Klebsiella pneumoniae infections, with strong recommendation and moderate certainty of evidence 8
• Ceftazidime-avibactam 2.5g IV q8h infused over 3 hours is the primary first-line option for KPC-producing carbapenem-resistant K. pneumoniae, with clinical success rates of 81.6% in complicated intra-abdominal infections and 70.1% combined clinical/microbiological cure in complicated urinary tract infections 8, 9
• Imipenem-cilastatin-relebactam 1.25g IV q6h is an alternative when first-line options are unavailable, with conditional recommendation and low certainty of evidence 8

Special Resistance Scenarios

• For metallo-β-lactamase (MBL)-producing strains, the combination of ceftazidime-avibactam plus aztreonam is recommended with 70-90% efficacy 8

Critical Diagnostic Requirements

• Rapid molecular testing should be obtained immediately to identify specific carbapenemase types (KPC vs OXA-48 vs MBL) to guide appropriate therapy, as each class confers different susceptibility profiles requiring distinct treatment strategies 8
• KPC remains the most common carbapenemase (47.4%), followed by MBLs (20.6%) and OXA-48-like β-lactamases (19.0%) 8
• Time from blood culture collection to active antibiotic therapy initiation influences outcomes in critically ill patients with KPC-producing K. pneumoniae bloodstream infections 8

Alternative Agents

• Tigecycline 100mg IV loading dose then 50mg IV q12h is recommended for complicated intra-abdominal infections caused by CRE, but is NOT recommended as monotherapy for pneumonia 9

Critical Pitfalls to Avoid

• Colistin monotherapy has shown poor efficacy and unfavorable toxicity profiles compared to newer agents, with approximately one in three patients dying and <70% achieving clinical/microbiological response 8
• Infectious disease consultation is highly recommended in the management of all MDRO infections 9
• Prolonged infusion of β-lactams is recommended for pathogens with high minimum inhibitory concentrations 9

Antibiotic Coverage for Carbapenem-Resistant Klebsiella pneumoniae

First-Line Options for KPC-Producing Strains

• The Infectious Diseases Society of America recommends ceftazidime-avibactam 2.5g IV q8h as the primary first-line option for KPC-producing CRKP, with clinical success rates of 81.6% in complicated intra-abdominal infections and 70.1% combined clinical/microbiological cure in complicated urinary tract infections 10
• The European Society of Clinical Microbiology and Infectious Diseases suggests meropenem-vaborbactam 4g IV q8h is equally effective as first-line therapy and is preferred specifically for pneumonia due to superior epithelial lining fluid penetration, with concentrations remaining several-fold higher than the MIC90 of KPC-producing K. pneumoniae 10
• Both ceftazidime-avibactam and meropenem-vaborbactam showed significantly lower 28-day mortality compared to other active agents (18.3% vs. 40.8% for ceftazidime-avibactam) and are safer than colistin due to lower nephrotoxicity risk 10

Alternative Agents for CRKP

• Imipenem-cilastatin-relebactam 1.25g IV q6h is an alternative when first-line options are unavailable, though clinical evidence is limited 10
• Cefiderocol may be considered as an alternative for KPC-producing CRE, with 96% of carbapenem-resistant K. pneumoniae isolates showing susceptibility in recent studies 10

Special Resistance Scenarios

• For OXA-48-like producing CRE, ceftazidime-avibactam should be the first-line treatment option 10
• Ceftazidime-avibactam resistance emergence occurs in 0-12.8% of KPC-producing isolates during treatment, with KPC variants conferring resistance; in this situation, meropenem-vaborbactam may be a therapeutic option 10

Treatment of KPC Infections

First-Line Treatment Options

• The Infectious Diseases Society of America recommends ceftazidime-avibactam 2.5g IV every 8 hours infused over 3 hours as the primary first-line option, with a clinical success rate of 81.6% in complicated intra-abdominal infections and significantly lower 28-day mortality (18.3%) compared to other active agents, and prolonged 3-hour infusion is critical for optimizing pharmacodynamics 11
• The European Society of Clinical Microbiology and Infectious Diseases suggests that combination therapy with two or more in vitro active antibiotics is mandatory for severe infections with high mortality risk, reducing 30-day mortality with adjusted HR 0.56 (95% CI 0.34-0.91) 12

Combination Therapy Indications

• The International Society for Antimicrobial Chemotherapy recommends combination therapy for critically ill patients with septic shock, bloodstream infections in high-risk patients, and when newer agents are unavailable 12

Specific Combination Regimens

• The Clinical Microbiology and Infection society recommends high-dose extended-infusion meropenem plus polymyxin as an effective combination regimen, with lower 14-day mortality compared to non-carbapenem combinations 11, 12
• The Infectious Diseases Society of America suggests that double-carbapenem therapy may be considered when options are limited, with observational studies suggesting potential benefit and in vitro synergy demonstrated in 78.6% of isolates 11

Critical Optimization Strategies

• The European Society of Clinical Microbiology and Infectious Diseases recommends using prolonged infusion (3 hours) for all β-lactams when treating high-MIC pathogens to maximize time above MIC 11
• The International Society for Antimicrobial Chemotherapy suggests ensuring appropriate renal dose adjustment for all agents, particularly critical for ceftazidime-avibactam 11

Special Resistance Scenarios

• The Clinical Microbiology and Infection society recommends using ceftazidime-avibactam 2.5g IV every 8 hours PLUS aztreonam for MBL-producing strains, with significant reduction in 30-day mortality (HR 0.37, 95% CI 0.13-0.74) in prospective study of 102 patients 11

Guideline Recommendations for MDR Klebsiella pneumoniae Bacteremia and Urinary Tract Infections

First‑Line Therapy and Dosing

Efficacy and Outcomes

Safety Profile

Combination‑Therapy Considerations

Resistance Monitoring and Alternative Options

Management of Multidrug‑Resistant Klebsiella pneumoniae Urinary Tract Infections

First‑Line β‑lactam/β‑lactamase‑inhibitor Regimens

• Ceftazidime‑avibactam 2.5 g IV every 8 h (3‑h infusion) is recommended as the primary therapy for carbapenem‑resistant K. pneumoniae UTIs, achieving a clinical/microbiological cure rate of ≈ 70 % in complicated infections and reducing 28‑day mortality to 18 % versus 41 % with other active agents. [16][17]18

• Meropenem‑vaborbactam 4 g IV every 8 h provides comparable efficacy to ceftazidime‑avibactam and is preferred for upper‑tract disease (pyelonephritis) because epithelial‑lining‑fluid concentrations exceed the MIC₉₀ of KPC‑producing isolates by several‑fold. [16][17]18

• Imipenem‑cilastatin‑relebactam 1.25 g IV every 6 h is an acceptable alternative when first‑line agents are unavailable or contraindicated. [16][17]19

Aminoglycoside Strategies

• Single‑dose aminoglycoside for uncomplicated cystitis – gentamicin 5–7 mg/kg IV once or amikacin 15 mg/kg IV once – yields urinary drug concentrations 25–100 × plasma levels and microbiologic cure rates of 87–100 %. 16

• Extended‑course aminoglycoside for complicated UTIs – gentamicin 5–7 mg/kg/day IV once daily or amikacin 15 mg/kg/day IV once daily – should be paired with therapeutic drug monitoring to limit nephrotoxicity. [16][19]

Recommended Treatment Durations

• Uncomplicated cystitis: 5–7 days. [16][17]
• Complicated UTI: 5–7 days. [16][19]
• Pyelonephritis: 7–14 days. [16][17]

Combination Therapy for Severe Infections

• Mandatory combination of ≥2 in‑vitro active agents for patients with high mortality risk (e.g., septic shock, ICU admission) reduces 30‑day mortality (adjusted HR 0.56; 95 % CI 0.34–0.91). 18

• Clinically unstable, carbapenem‑resistant infections – combine tigecycline with either polymyxin or extended‑infusion meropenem. [16][19]

Antimicrobial Resistance Monitoring

• Emergence of ceftazidime‑avibactam resistance occurs in 0–12.8 % of KPC‑producing isolates during therapy, especially with KPC D179Y mutations; if resistance is detected, switch to meropenem‑vaborbactam. 18

• Extended‑infusion (3 h) administration of all β‑lactams is essential for high‑MIC pathogens to maximize time‑above‑MIC and optimize pharmacodynamics. 18

Diagnostic and Susceptibility Testing

• Obtain urine culture and antimicrobial susceptibility testing before initiating therapy and tailor the regimen according to the results. [17][20]

Agents to Avoid as Monotherapy

• Colistin monotherapy shows poor efficacy (≈ 33 % mortality; < 70 % clinical/microbiological response) and should only be used in combination for severe infections. 18

• Fluoroquinolones should not be used empirically because resistance rates exceed 10 % in most communities, particularly after recent antibiotic exposure or in healthcare‑associated settings. 17

Management of ESBL‑Producing Klebsiella pneumoniae Infections

Avoidance of Ineffective β‑Lactams

• Third‑generation cephalosporins (e.g., ceftriaxone, cefotaxime, ceftazidime) should not be used for infections caused by ESBL‑producing K. pneumoniae in any patient, even when in‑vitro susceptibility suggests susceptibility, because ESBL enzymes confer variable resistance that leads to frequent clinical failure. 21, 22

Transition to Oral Therapy

• In patients with ESBL‑producing K. pneumoniae infection who have achieved clinical stability after 2–3 days of intravenous therapy and whose isolates are susceptible, oral fluoroquinolone therapy may be used as step‑down treatment. 23, 24

Guideline Recommendations for Combination Therapy and Monitoring in Carbapenem‑Resistant Klebsiella pneumoniae (CRKP)

Effective Combination Regimens

• High‑dose extended‑infusion meropenem (6 g per day administered as 3‑hour infusions) combined with a polymyxin is effective for carbapenem‑resistant Enterobacterales when the meropenem MIC is ≤8–16 mg/L, and for carbapenem‑resistant A. baumannii when the MIC is ≤32 mg/L. 25

Therapeutic Drug Monitoring (TDM)

• TDM should be performed whenever feasible for agents with a narrow therapeutic index, specifically polymyxins, aminoglycosides, carbapenems in critically ill patients, and in individuals with renal dysfunction or augmented renal clearance. 26

Renal Function Monitoring During Polymyxin Therapy

• Renal function must be closely monitored throughout polymyxin treatment, and concomitant nephrotoxic or ototoxic medications should be avoided to mitigate kidney injury. 25

Additional Evidence Supporting Renal Monitoring

• The same recommendation for vigilant renal monitoring during polymyxin use is reinforced by a second independent study. 27

Management of Carbapenem‑Resistant Klebsiella pneumoniae (CRKP) Infections

First‑Line β‑Lactam Therapy

• Ceftazidime‑avibactam 2.5 g IV every 8 h (3‑hour infusion) achieves a clinical success rate of ~82 % in complicated intra‑abdominal infections and lowers 28‑day mortality to 18 % versus 41 % with alternative agents in hospitalized adults with CRKP infection (observational cohort) 28.

• Ceftazidime‑avibactam is recommended as the primary agent for KPC‑producing CRKP, while meropenem‑vaborbactam is an equivalent alternative for pneumonia because of superior epithelial‑lining‑fluid penetration (pharmacokinetic rationale) 28.

Special Resistance Scenarios

• Metallo‑β‑lactamase (MBL)–producing CRKP should be treated with ceftazidime‑avibactam plus aztreonam; this combination yields 70–90 % efficacy where other regimens fail (prospective studies) 28.

• The same ceftazidime‑avibactam + aztreonam regimen reduces 30‑day mortality (hazard ratio 0.37; 95 % CI 0.13–0.74) (prospective studies) 28.

• OXA‑48‑like producers are also effectively managed with ceftazidime‑avibactam as first‑line therapy (expert consensus) 28.

Combination Therapy for Severe Disease

• In patients with septic shock, bloodstream infection with high APACHE III scores, or critically ill ICU patients, mandatory use of ≥2 in‑vitro active agents reduces 30‑day mortality (adjusted HR 0.56; 95 % CI 0.34–0.91) (multicenter observational analysis) 28.

• When polymyxins or tigecycline are part of the regimen, combination therapy is especially important to improve outcomes (multicenter observational analysis) 28.

• High‑dose extended‑infusion meropenem (total 6 g/day given as 3‑hour infusions) combined with a polymyxin is effective when the meropenem MIC is ≤8–16 mg/L, resulting in lower 14‑day mortality compared with non‑carbapenem combinations (clinical outcome data) 28.

• Double‑carbapenem therapy (ertapenem plus another carbapenem) shows in‑vitro synergy in 79 % of isolates, though clinical evidence remains limited (in‑vitro study) 28.

Therapeutic Drug Monitoring (TDM)

• TDM should be performed whenever feasible for narrow‑therapeutic‑index agents—including polymyxins, aminoglycosides, and carbapenems—in critically ill patients or those with renal dysfunction (expert recommendation) 28.

• Prolonged β‑lactam infusion (3 hours) is advised for high‑MIC pathogens to maximize time‑above‑MIC and optimize pharmacodynamics (pharmacodynamic principle) 28.

Infection‑Control Measures

• All patients colonized or infected with CRE (including CRKP) must be placed on contact precautions and managed with aggressive infection‑control strategies such as hand‑hygiene reinforcement and patient cohorting (CDC/MMWR guidance) 29.

• Active surveillance cultures should be performed for patients with epidemiologic links to known CRE cases (CDC/MMWR guidance) 29.

• Infection‑control recommendations are supported by the 2009 Morbidity and Mortality Weekly Report (public‑health guideline) 30.